A new research document with title ‘Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline Review, H1 2017’ covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis and important players/vendors such as Enzo Biochem Inc, EpiVax Inc, Etubics Corp etc. The report will help user gain market insights, future trends and growth prospects for forecast.
Request a sample report @ https://www.htfmarketreport.com/sample-report/560271-human-immunodeficiency-virus-2
Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline Review, H1 2017
The latest Pharmaceutical and Healthcare disease pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline Review, H1 2017, provides an overview of the Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline landscape.
HIV is a virus which attacks the immune system, and weakens ability to fight infections and disease. Symptoms include fever, sore throat, body rash, joint pain, muscle pain and swollen glands. The most common ways HIV is spread are by having vaginal or anal intercourse without a condom with someone who has HIV/AIDS, sharing needles or syringes with someone who has HIV/AIDS, being deeply punctured with a needle or surgical instrument contaminated with HIV and getting HIV-infected blood, semen, or vaginal secretions into open wounds or sores.
The Pharmaceutical and Healthcare latest pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 1, 16, 46, 37, 1, 4, 114, 75 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 17, 15, 57 and 66 molecules, respectively.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/560271-human-immunodeficiency-virus-2
Companies Mentioned in the Report
Advanced Genetic Systems Inc
Akshaya Bio Inc
Altor BioScience Corp
Amarna Therapeutics BV
American Gene Technologies International Inc
Amunix Operating Inc
Antigen Express Inc
Argos Therapeutics Inc
Arno Therapeutics Inc
B Cell Design SAS
Biological Mimetics Inc
Boehringer Ingelheim GmbH
Bolder Biotechnology Inc
Bristol-Myers Squibb Company
Bukwang Pharm Co Ltd
C4X Discovery Holdings PLC
Celldex Therapeutics Inc
Chipscreen Biosciences Ltd
Cocrystal Pharma Inc
ContraVir Pharmaceuticals Inc
Critical Outcome Technologies Inc
Dong-A Socio Holdings Co Ltd
Enzo Biochem Inc
eTheRNA Immunotherapies NV
Excision BioTherapeutics Inc
FIT Biotech Oy
Fountain Biopharma Inc
Frontier Biotechnologies Co Ltd
Galmed Pharmaceuticals Ltd
GeoVax Labs Inc
Gilead Sciences Inc
GW Pharmaceuticals Plc
Hadasit Medical Research Services & Development Ltd
Hanmi Pharmaceuticals Co Ltd
Heat Biologics Inc
iCo Therapeutics Inc.
ID Pharma Co Ltd
Immune Response BioPharma Inc
Immune Therapeutics Inc
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=560271
ImQuest Life Sciences Inc
Innovative Targeting Solutions Inc
Inovio Pharmaceuticals Inc
Japan Tobacco Inc
Johnson & Johnson
Karyopharm Therapeutics Inc
KPI Therapeutics Inc
Longevity Biotech Inc
Medestea Research & Production SpA
Merck & Co Inc
Mycenax Biotech Inc
NeED Pharma srl
New World Laboratories Inc
Oncolys BioPharma Inc
Orbis Biosciences Inc
Peregrine Pharmaceuticals Inc
Pharis Biotec GmbH
Phoenix Biotechnology Inc
Profectus BioSciences Inc
Relmada Therapeutics Inc
Rodos BioTarget GmbH
Samjin Pharmaceutical Co Ltd
Sangamo Therapeutics Inc
Sanofi Pasteur SA
Sirenas Marine Discovery LLC
Solon Eiendom ASA
Spring Bank Pharmaceuticals Inc
Starpharma Holdings Ltd
Susavion Biosciences Inc
Taiga Biotechnologies Inc
TaiMed Biologics Inc
Takara Bio Inc
Takeda Pharmaceutical Company Ltd
Transgene Biotek Ltd
TVAX Biomedical Inc
United Biomedical Inc
Vault Pharma Inc
VG Life Sciences Inc
Vichem Chemie Research Ltd
ViiV Healthcare Ltd
Zydus Cadila Healthcare Ltd
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/560271-human-immunodeficiency-virus-2
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218